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PAST
Oesophagectomy is the cornerstone of treatment for
esophageal cancer. Extended lymphadenectomy may
reduce locoregional failure and improve long-term sur-
vival. However, the value of lymph node dissection for
locoregional tumor control has been debated since the
introduction of neoadjuvant chemoradiotherapy. Neoadju-
vant chemoradiotherapy leads to tumor shrinkage and
results in a higher proportion of resections with tumor-
negative resection margins and tumor-free lymph nodes.1
Studies have shown that the number of removed lymph
nodes is associated with improved survival for patients who
underwent surgery without neoadjuvant chemoradiother-
apy. However, this positive correlation is lost in patients
who underwent neoadjuvant chemoradiotherapy followed
by surgery.2,3
Besides its role in locoregional tumor control, an
extensive lymphadenectomy may improve tumor staging.
Accurate pathological staging is essential for
prognostication.4
PRESENT
In 2013, the number of lymph nodes removed was
introduced as a quality indicator in the Dutch Upper gas-
trointestinal Cancer Audit (DUCA). This indicator is
defined as ‘‘the percentage of patients with at least 15
retrieved LNs.’’ The purpose of our study was to evaluate
trends in the number of retrieved lymph nodes and the
proportion of patients with C 15 LNs in the resection
specimen.
Between 2011 and 2016, the median number of lymph
nodes removed increased from 15 to 20. The percentage of
patients with at least 15 lymph nodes removed also
increased from 50 to 80% on a national level.5 There was a
wide variation in the percentage of patients with at least 15
lymph nodes removed between hospitals (0–77%). In 2016,
hospital variation decreased but was still considerable
(between 50 and 98%).
FUTURE
Given the importance of lymph node retrieval for
locoregional control and accurate staging, a higher number
of lymph nodes removed will likely improve the quality of
care. However, it remains unknown if the increased num-
ber of removed lymph nodes was due to extended surgery
or more accurate pathological examination of the resection
specimen. The DUCA does not contain long-term follow-
up data. Hence, the study could not report on the associa-
tion of number of lymph nodes removed and survival after
neoadjuvant chemoradiotherapy.
An argument for the use of this indicator in clinical
auditing is that there is a clinically relevant variation in
outcomes between hospitals. This may lead to improve-
ment initiatives in the hospitals underperforming.
Continues use of this indicator in the DUCA may reduce
variation and improve outcomes on a national level.
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